Skip to Content

Adverse Drug Reactions Linked to Hydroxychloroquine Up in 2020

WEDNESDAY, Jan. 27, 2021 -- The number of adverse drug reactions (ADRs) associated with hydroxychloroquine and chloroquine more than doubled in 2020 compared with 2018 and 2019, according to a research letter published online Jan. 26 in the Annals of Internal Medicine.

Justine Perez, Pharm.D., from the Grenoble Alpes University Hospital in France, and colleagues quantified the change in number and type of reported ADRs associated with hydroxychloroquine and chloroquine since the beginning of the COVID-19 pandemic compared to 2018 and 2019.

A total of 21,305 reports of 152,201 suspected ADRs concerning chloroquine and hydroxychloroquine were extracted from the U.S. Food and Drug Administration Adverse Event Reporting System database from Jan. 1, 2018, to Sept. 30, 2020. The researchers found that in 2020, the number of reported ADRs for chloroquine and hydroxychloroquine more than doubled (11,493 and 89,607, respectively) compared with the same months in 2018 (4,681 and 25,035, respectively) and 2019 (5,131 and 37,559, respectively). In 2020, the most represented countries were Canada, the United States, France, Spain, and Italy. Overall, 97.1 percent of the ADRs reported in 2020 were considered serious compared with 73.4 and 84.8 percent in 2018 and 2019, respectively. Similarly, 5.1 percent of reported cases in 2020 were fatal compared with 3.1 and 1.9 percent in 2018 and 2019, respectively.

"The dramatic increase in reported ADRs associated with chloroquine and hydroxychloroquine during the SARS-CoV-2 pandemic raises concerns about the potential harms of widespread use of these medications in the absence of proven benefit," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Posted: January 2021

Read this next

Response to One Dose of COVID-19 Vaccine Strong for Previously Infected

TUESDAY, March 2, 2021 -- Individuals with previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection generate strong responses to one dose of the BNT162b2...

​IL-6 Receptor Antagonists Benefit Critically Ill With COVID-19​

TUESDAY, March 2, 2021 -- Treatment with interleukin-6 receptor antagonists tocilizumab and sarilumab improves outcomes among critically ill patients with COVID-19 receiving organ...

Walmart Expands COVID-19 Vaccination Program

MONDAY, March 1, 2021 -- Walmart said it will expand its COVID-19 vaccination program to more than 1,400 pharmacies in 35 states. The retailer will also partner with local...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.